# US 11,433,074 B2 · Methods of treating glioblastoma

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,433,074 B2
- Document ID: US11433074B2
- Status: Granted
- Kind: B2
- Application number: 16/626,282
- Filed: 2018-06-22
- Published: 2020-04-16
- Granted: 2022-09-06
- Earliest claimed: 2017-06-22
- Assignees: Triact Therapeutics, Inc.
- Applicants: Triact Therapeutics, Inc.
- Inventors: Thomas F. White
- Web page: https://patentgrep.com/patent/US11433074B2

## CPC

- A61K 31/522: having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A61P 35/00: Antineoplastic agents
- C12Q 1/6827: for detection of mutation or polymorphism
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/154: Methylation markers
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Disclosed herein are methods and compounds for treating glioblastoma with iniparib. Also disclosed herein is a method of selecting subjects having a glioblastoma for treatment based on a biomarker panel.

## Claims

### Claim 1

A method of treating glioblastoma in a subject in need thereof, comprising administering to the subject:
about 8 mg/kg of 4-iodo-3-nitrobenzamide or a salt, metabolite or prodrug thereof;
about 75 mg/m2 of temozolomide; and
radiation.

### Claim 2 (depends on 1)

The method of claim 1, wherein about 60 Gy of radiation is administered to the subject over a course of about six weeks.

### Claim 3 (depends on 1)

The method of claim 1, wherein the 4-iodo-3-nitrobenzamide or the salt, metabolite or prodrug thereof is administered to the subject once a day and twice a week.

### Claim 4 (depends on 1)

The method of claim 1, wherein the 4-iodo-3-nitrobenzamide or the salt, metabolite or prodrug thereof is administered to the subject for about six weeks.

### Claim 5 (depends on 1)

The method of claim 1, wherein temozolomide is administered to the subject daily.

### Claim 6 (depends on 1)

The method of claim 1, wherein temozolomide is administered to the subject for about six weeks.

### Claim 7 (depends on 1)

The method of claim 1, wherein upon completion of about six weeks of treatment with 4-iodo-3-nitrobenzamide or the salt, metabolite or prodrug thereof, temozolomide, and radiation, the subject receives a treatment break of about four weeks.

### Claim 8 (depends on 1)

The method of claim 1, wherein the 4-iodo-3-nitrobenzamide or the salt, metabolite or prodrug thereof and the temozolomide is administered to the subject for about 1-6 cycles, wherein a single cycle is about 28 days.

### Claim 9 (depends on 8)

The method of claim 8, wherein the temozolomide is administered to the subject on Days 1-5 of each cycle.

### Claim 10 (depends on 1)

The method of claim 1, wherein the 4-iodo-3-nitrobenzamide or the salt, metabolite or prodrug thereof is formulated for parenteral administration, wherein the parenteral administration comprises intravenous, intra-arterial, intracranial, intracerebral, intracerebroventricular, or intrathecal administration.

### Claim 11 (depends on 1)

The method of claim 1, wherein the 4-iodo-3-nitrobenzamide or the salt, metabolite or prodrug thereof is formulated as an injection or as an infusion.

### Claim 12 (depends on 1)

The method of claim 1, wherein the glioblastoma is a primary glioblastoma or a secondary tumor.

### Claim 13 (depends on 1)

The method of claim 1, wherein the subject has a grade III or grade IV glioblastoma.